

19th & 20th of May 2009  
 Steinbeis-Hochschule-Berlin

fon +49 40 878790 - 316  
 cell +49 172 322 7948  
 fax +49 40 878790 - 122  
 mail [Ahlers@IPB-AG.COM](mailto:Ahlers@IPB-AG.COM)  
 web [WWW.IPB-AG.COM](http://WWW.IPB-AG.COM)

**IPB AG**  
 Dr. Benedikt Ahlers  
 Head IP Sales & Development  
 Stephansplatz10  
 20354 Hamburg

Information about the company

Sector of activity: Impact Modifier – Polymer additive on basis of nano technology\*

The patent covers an innovative process to obtain a nano-structure of polyurethane in a reactive diluent. This improves the physical properties of plastic materials, such as transparency, impact strength, pull-out and shear strength according to the requirements of the vendor. Although this material can be considered as an “additive”, it can actually comprise more than 50 percent of the final reactive diluent, so it can capture a significant share of that market. This assumption is further reinforced by the fact that the cost of this additive is not far above the polymers it is added to. Thus, using it does not need to impact the final price significantly.

Information about the future market: According to a recent Frost & Sullivan study, the European market volume for Emulsion Polymers in 2007 was 3.8 bn EUR, growing to 4.2 bn EUR in 2010.

This invention can be used to improve properties of a wide range of materials such as polymers, adhesives, coatings, glues, lacquers, etc. Therefore this invention has not only the potential of expanding the use of the materials, but also the capability to generate new market opportunities.

existing partners/shareholders: \*) 100% Dritte Patentportfolio Beteiligungsgesellschaft mbH & Co. KG; 12529 Schönefeld

valuation: € 200 Mio.

founder month/year: 2007

legal form:

Staff: 1

turnover:	200	2009 exp	2010 exp	2011 exp
Mio				

Information about the investment

equity capital: to be negotiated

exit for: Secondary Purchase, Trade Sale

reference investment: VC with proven records in advanced materials or chemical industries  
 in the corporate

19th & 20th of May 2009  
 Steinbeis-Hochschule-Berlin

fon +49-351-796-5720  
 cell  
 fax +49-351-796-5721  
 mail juergen.hofinger@namos.de  
 web www.namos.de

**Namos GmbH**  
 Dr. Jürgen Hofinger  
 Managing Director  
 Tatzberg 47  
 01307 Dresden, Germany

Information about the company

Sector of activity: Namos technology reduces the need of precious metals in exhaust gas catalysts by up to 50% without raising system costs significantly. This technology is based on Namos unique biotemplating platform for industrial surfaces, where complex biologic molecules (biotemplates) establish designed nanostructured metallic or ceramic surfaces. Namos is a research and development company with a business model to sell or licence technologies.

Information about the future market: In the current project markets are automotive catalysts (OEM, after sales market) and exhaust gas catalysts for non automotive applications (stationary machines, ships, small motors etc.). The value of the precious metal that can be saved by the technology is about 3 Billion Euros. The platform technology has additional markets to be explored in the future.

existing partners/shareholders: Dr. Juergen Hofinger, Steffen Roos, Tanja Richter, Daniela Keck, Nanostart AG, KfW

currency: n.a.

founded month/year : 03/1998

legal form: GmbH

Staff: 8

turnover:	200	2009 exp	2010 exp	2011 exp
Mio	*	*	*	*

Information about the investment

equity capital: 1 Mio. Euro with at least 500 TEURO already covered by previous shareholders

use for: market launch

preferred investment: no preferences  
 in the corporate

19th & 20th of May 2009  
 Steinbeis-Hochschule-Berlin

fon  
 cell +46709732665  
 fax  
 mail [Krim@nanologica.com](mailto:Krim@nanologica.com)  
 web [www.nanologica.com](http://www.nanologica.com)

**Nanologica AB**  
 Krim Talia  
 CEO  
 Uppsala Science Park  
 75183 Uppsala, Sweden

Information about the company

Sector of activity: Nanologica AB is a leading Swedish materials development company - structured around its two major business sections: NLAB Bio and NLAB Energy. Nanologica is commercializing a strong patent portfolio on nanoporous materials. NLAB Energy is commercializing new materials with applications in the renewable energy sector with focus on DSSC, and NLAB Bio is focusing on materials with applications in diagnostics and drug delivery.

Information about the future market: Nanologica earns money on licensing deals, royalties and material sales. Nanologica is targeting big markets with high annual growth rates. Nanologica has been customer financed since day one.

existing partners/shareholders: Krim Talia, Alfonso Garcia-Bennett, Saeid Esmailzadeh, Giovanni Fili, Ashkan Poya, Hernan Miguez, + 4 Syndicated Angel Investors.

liquidity: 0.5

founded month/year: 2004

legal form: Limited Liability Company

Staff: 8

turnover:	200	2009 exp	2010 exp	2011 exp
Mio	0.5	2	5	10

Information about the investment

equity capital: 3 Mio. EUR

use for: Pilot Plant

reference investment: Angel, Corporate  
 on the corporate

19th & 20th of May 2009  
Steinbeis-Hochschule-Berlin

fon  
cell  
fax  
mail [tjahn@mmm.com](mailto:tjahn@mmm.com)  
web [www.3M.com](http://www.3M.com)

**3M New Ventures**

Tobias Jahn  
New Ventures Manager  
ESPE Platz  
82229 Seefeld

Information about the company

Sector of activity / investments: 3M New Ventures is broadly interested in companies and cooperations in industries including automotive & mobility, architecture, design, light management, clean-tech, bio-tech, health care, software, water treatment, nanotechnology, new/ smart materials and others. We're looking for entrepreneurs who are tackling problems in creative and innovative ways. As a corporate venturer, we're also looking for investments with the potential for significant financial return.

19th & 20th of May 2009  
Steinbeis-Hochschule-Berlin

fon +49 (0)621 60 76801  
cell -  
fax +49 (0)621 60 76819  
mail [info\\_vc@basf.com](mailto:info_vc@basf.com)  
web [www.basf-vc.de](http://www.basf-vc.de)

**BASF Venture Capital GmbH**

Dirk Nachtigal / Dr. Josef R.Wünsch  
Managing Directors  
4. Gartenweg - Z25  
67063 Ludwigshafen

Information about the company

Sector of activity / investments: BASF Venture Capital GmbH is the corporate venture capital company of BASF Group. We invest worldwide in start up companies and venture capital funds. Innovative technologies, which are based on chemistry as well as new materials, are the focus of our attention.

Year of founding: 2001

Offices: Ludwigshafen - Fremont (USA) - Hong Kong (China) - Tokyo (Japan)

Minimum Investment: 1 Mio. €

Financing Stages: Early Stage

Investment Focus:

- Plant Biotechnology
- Industrial Biotechnology
- Raw Material Change
- Nanotechnology
- Energy Management

19th & 20th of May 2009  
Steinbeis-Hochschule-Berlin

fon +41 44 269 60 69  
cell +41 79 251 32 09  
fax +41 44 269 60 65  
mail [vui@cti-invest.ch](mailto:vui@cti-invest.ch)  
web [www.cti-invest.ch](http://www.cti-invest.ch)

**CTI Invest**

Jean-Pierre Vuilleumier  
Managing Director  
Seehofstrasse 6  
8008 Zurich, Switzerland

Information about the company

Sector of activity / investments: CTI Invest is the leading financing platform for High Tech companies in Switzerland. We are organizing Match Making and Networking events for Investors and High Tech companies on a regularly basis. As of today we count approx. 70 investor members either from abroad or from Switzerland.

Our achievements since the foundation in 2003 as a non-profit organization:

24 Swiss Venture Days at the SIX Exchange in Zurich  
6 Venture Days of Swiss Technology abroad, mostly in Munich  
>150 Swiss High Tech companies presented to the investor members  
> 60 Video podcasts (today as live takes) for the investors that can not attend  
5 CEO Days, with more than 200 participants each year  
1/2 of the presented companies eventually got financed  
Cumulated financing volume > CHF 200 Mio. since 2003

Our focus is:  
Biotech & Lifescience (including Medtech)  
Micro & Nanotechnology  
Information & Communication  
Cleantech

The companies we present are either looking for early or later stage financing (first round). Almost all of the presented companies are in the Swiss High Tech support program CTI Start-up and benefit from our services, e.g. pitch training, free of charge.

CTI Invest is financing its activities with an annual membership fee of the investors and with partnering and sponsorships.

Our next events will be:

3.6.2009 25th Swiss Venture Day in Zurich (SIX, starting at 1400)  
17.6.2009 5th Venture Day of Swiss Technology in Munich

For more information please check our webpage to find out more about:

- Who is already an investor member
- Who the board and management team are
- Which companies were presented
- What events are coming up
- When and where they will take place

Note that there is a members only section, where the company profiles and the full podcasts can be found.

19th & 20th of May 2009  
Steinbeis-Hochschule-Berlin

fon +49 521 2997-205  
cell  
fax +49 521 2997-206  
mail [info@gruenderfonds-bow.de](mailto:info@gruenderfonds-bow.de)  
web [www.gruenderfonds-bow.de](http://www.gruenderfonds-bow.de)

**Gründerfonds Bielefeld-Ostwestfalen  
GmbH & Co. KG**

Dr. Michael Lübbehusen  
Partner, Fondsmanager  
Meisenstrasse 96  
33607 Bielefeld

Information about the company

Sector of activity / investments: In cooperation with 'Sparkasse Bielefeld', 'NRW.BANK' and a large number of well-known entrepreneurs from East Westphalia-Lippe as fund investors, the seed fund "Bielefeld-Ostwestfalen" is investing in young companies of strong growth potential in the aforementioned area. For this purpose, a total of 10m EUR have been raised to be invested in the forthcoming years with first round investments up to 500k EUR. The seed fund "Bielefeld-Ostwestfalen" is one of a total number of seven regional seed funds invested by the NRW.BANK in the NRW area (North Rhine-Westphalia).

Among others, the investment focus aims at Mechanical Engineering, Process and Automation Engineering, IT, Communication and Nanotechnology, Material Science, Life Science and Biotechnology.

19th & 20th of May 2009  
Steinbeis-Hochschule-Berlin



fon +49 (89) 20 70 49-0  
cell +49 (172) 810 0780  
fax +49 (89) 20 70 49-99  
mail [olaf@targetpartners.de](mailto:olaf@targetpartners.de)  
web [www.targetpartners.de](http://www.targetpartners.de)

## Target Partners GmbH

Olaf Jacobi  
Partner  
Kardinal-Faulhaber-Straße10  
80333 München

### Information about the company

Sector of activity / investments: Target Partners invests predominantly in the German speaking markets. As the world's strongest export region, the European technology champion and with a huge domestic market, this region provides an excellent base for building strong and fast growing companies.

We invest in companies in IT, the Web, media, semiconductors, telecommunications, alternative energies, environmental technologies, and micro- and nano-technologies. In some cases we already invest when there is little more than an idea or a prototype. But often our portfolio companies already have a finished product or even first customers.

With 225 million Euro under management, Target Partners is one of the leading venture capital investors in Germany.

The partners of Target Partners have years of collective experience as successful managers, entrepreneurs and venture capital investors in Europe and the USA. We founded or led companies ourselves, developed or sold technology products ourselves. We have seen numerous companies through to IPO and beyond. We understand the challenges an entrepreneur faces and that the road to success often isn't simple and straight.

Both in Europe and the USA Target Partners has a large network in industry and venture capital. We open doors for you to customers, business partners, experienced managers and financial markets. We support you in business development, in international expansion, in closing OEM or distribution contracts, and in acquisition decisions. In addition, several dozen European and US entrepreneurs and top managers, as well as a number of US venture capitalists, have personally invested in our funds.

19th & 20th of May 2009  
Steinbeis-Hochschule-Berlin

fon +49 211 179 2000  
cell  
fax +49 211 171 9000  
mail [info@bonnekamp-sparing.de](mailto:info@bonnekamp-sparing.de)  
web [www.bonnekamp-sparing.de](http://www.bonnekamp-sparing.de)

**Bonnekamp & Sparing  
European Patent and Trademark Law Firm**

Rolf K. Sparing and Dr. Andreas Hübel

Goltsteinstraße 19  
40211 Düsseldorf, Germany

Information about the company

Sector of activity / investments:

- Protection for inventions (patents, utility models)
- Protection for trademarks, service marks and designs
- Patent and Know-how licenses, R & D and co-operation contracts
- Inventor's Rights and remuneration of employee-inventors
- Expert opinion on Intellectual Property situation (e.g. before extensive R & D)
- Intellectual Property searches and review
- Intellectual Property litigation against infringement
- Opposition and nullity suits against Third party's IP Rights
- IP due diligence
- Counsel to start-ups for IP strategy, secrecy handling, contracts and funding

Our Firm is counsel to German and foreign companies for the protection of Intellectual Property worldwide, in particular inventions, and for enforcement of Rights against competitors. The service to our clients includes cost optimized solutions and strategies. We were repeatedly able to significantly downsize the patent costs of our clients.

Focus of our Firm are inventions in the field of mechanical engineering, in particular automotive suppliers, physics, in particular nano-physics, computer-related invention, semiconductors and optics, and chemistry, in particular solid state chemistry, Life and Crop Sciences. Bonnekamp & Sparing is member of BIO Deutschland. Please check our homepage for profiles of attorneys.

We further have significant experience in solving complex inventor's remuneration problems and finding adequate provisions in the respective balance for late payments. In particular when entering fresh capital or going public, it is often found that remuneration legally